×
About 7,045 results

ALLMedicine™ Aphasia Center

Research & Reviews  2,586 results

MAPT Q336H mutation: intra-familial phenotypic heterogeneity in a new Italian family.
https://doi.org/10.1111/ene.15250
European Journal of Neurology; Villa C, Rossi G et. al.

Jan 13th, 2022 - Q336H is a rare MAPT mutation, previously found in a single patient with behavioral variant of FTD and tau pathology (Pick bodies). Here, we describe the clinical characteristics of two members of a new family, carrying the Q336H MAPT mutation. Cl...

Rare variants in TP73 in a Frontotemporal Dementia cohort link this gene with primary p...
https://doi.org/10.1111/ene.15248
European Journal of Neurology; Tábuas-Pereira M, Santana I et. al.

Jan 13th, 2022 - TP73 was recently reported to cause Amyotrophic Lateral Sclerosis (ALS). ALS and Frontotemporal Dementia (FTD) are considered to be part of a continuum. We aimed to investigate whether TP73 variants may be associated with FTD. We studied a thoroug...

Exploring the functional connectivity characteristics of brain networks in post-stroke ...
https://doi.org/10.21037/apm-21-2750
Annals of Palliative Medicine; Xu X, Ren C et. al.

Jan 13th, 2022 - In this study, resting-state functional magnetic resonance imaging (rs-fMRI) was used to investigate the characteristics of functional connectivity of brain networks in patients with post-stroke global aphasia (PGA). PGA patients hospitalized in W...

Motivated semantic control: Exploring the effects of extrinsic reward and self-referenc...
https://doi.org/10.1111/jnp.12272
Journal of Neuropsychology; Souter NE, Stampacchia S et. al.

Jan 12th, 2022 - Recent insights show that increased motivation can benefit executive control, but this effect has not been explored in relation to semantic cognition. Patients with deficits of controlled semantic retrieval in the context of semantic aphasia (SA) ...

Utility of the Repeat and Point Test for Subtyping Patients With Primary Progressive Ap...
https://doi.org/10.1097/WAD.0000000000000482
Alzheimer Disease and Associated Disorders; Seckin M, Ricard I et. al.

Jan 11th, 2022 - Primary progressive aphasia (PPA) may present with three distinct clinical sybtypes: semantic variant PPA (svPPA), nonfluent/agrammatic variant PPA (nfvPPA), and logopenic variant PPA (lvPPA). The aim was to examine the utility of the German versi...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  107 results

Genetic and Cognitive Predictors of Aphasia Treatment Response
https://clinicaltrials.gov/ct2/show/NCT05179538

Jan 5th, 2022 - Incomplete understanding of patient-specific factors that determine whether someone will respond well to language therapy after stroke limits the development of methods to target or account for sources of variability. There is a strong likelihood ...

Picture Naming in the Context of Image Type and Response Variety in People With and Without Aphasia
https://clinicaltrials.gov/ct2/show/NCT05164380

Dec 20th, 2021 - Qulity assurance: To verify the presence and reliability of all subject data, the following items were checked during these visits using a checklist: Presence of informed consent, presence of all data requested in the questionnaire, correctness of...

Transcranial Alternating Current Stimulation (tACS) in Aphasia
https://clinicaltrials.gov/ct2/show/NCT04375722

Nov 30th, 2021 - Aphasia is a debilitating disorder, typically resulting from damage to the left hemisphere, that can impair a range of communication abilities, including language production and comprehension, reading, and writing. Approximately 180,000 new cases ...

TMS in Aphasia Recovery
https://clinicaltrials.gov/ct2/show/NCT04777214

Nov 26th, 2021 - Stroke often causes substantial problems in speaking or understanding speech. Treatments for these problems are currently very limited. Limited studies to date suggest that repetitive Transcranial Magnetic Stimulation (TMS) to the side of the brai...

Executive Training and Anomia Therapy in Chronic Post-stroke Aphasia
https://clinicaltrials.gov/ct2/show/NCT05101408

Nov 18th, 2021 - Aphasia is a devastating acquired language impairment mainly caused by stroke, in which anomia is a quintessential clinical feature. If speech-language therapy (SLT) has been shown to be effective for persons with aphasia, the relative efficiency ...

see more →

News  98 results

YTB323 Shows Encouraging Efficacy in Relapsed/Refractory DLBCL
https://www.onclive.com/view/ytb323-shows-encouraging-efficacy-in-r-r-dlbcl

Jan 4th, 2022 - YTB323, a novel, autologous CD19-directed CAR-T cell therapy, displayed a favorable safety profile and efficacy across multiple dose levels in adult patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL), according to results from...

Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL
https://www.onclive.com/view/axi-cel-demonstrates-60-efs-improvement-in-second-line-relapsed-refractory-lbcl

Jan 4th, 2022 - Axicabtagene ciloleucel (axi-cel; Yescarta) led to a 60% improvement in event-free survival (EFS) compared with standard-of-care (SOC) chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL), accord...

Most States Lack Specific Prehospital Guidelines on Transport of Suspected LVO Patients
https://www.medscape.com/viewarticle/959115

Sep 22nd, 2021 - (Reuters Health) - Most U.S. states do not have emergency medical services (EMS) guidelines that address transport of patients with suspected stroke caused by large vessel occlusion (LVO), and among those that do, there is substantial variability ...

Blood Test Discerns Alzheimer's From Other Dementia With High Accuracy
https://www.medpagetoday.com/neurology/alzheimersdisease/94177

Aug 23rd, 2021 - Two blood markers, phosphorylated tau 217 (p-tau217) and phosphorylated tau 181 (p-tau181), showed strong diagnostic performances for Alzheimer's disease and discriminated Alzheimer's from frontotemporal lobar denervation (FTLD) syndromes and norm...

DLBCL: Managing Toxicities of CAR T-Cell Therapy
https://www.onclive.com/view/dlbcl-managing-toxicities-of-car-t-cell-therapy

Apr 2nd, 2021 - Transcript: Stephen J. Schuster, MD: There are 2 unique toxicities of CAR T cells that physicians and oncologists will learn about as they begin to manage patients: cytokine release syndrome and neurotoxicity. Cytokine release syndrome is t...

see more →

Patient Education  10 results see all →